Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, what steps he is taking to make Kadcyla available to patients in the UK.
Trastuzumab emtansine (Kadcyla) has been funded and available to National Health Service patients in England since 2013 for the treatment of patients with HER2-positive unresectable, locally advanced or metastatic breast cancer after trastuzumab and a taxane.